Humira Patent Protection
17 patents · AbbVie Inc.
D
Patent Strength
41/100
17
Total Patents
1
Assignees
2029
Earliest Expiration
2041
Latest Expiration
Patent Details
| Patent # | Title | Assignee | Granted | Expires | Claims | Status |
|---|---|---|---|---|---|---|
| 10005225 | high-performance chemical composition with CMOS properties | AbbVie Inc. | Nov 5, 2013 | Jul 17, 2030 | 6 | 4.3y left |
| 10005226 | Method for low-latency diagnosis using lidar | AbbVie Inc. | Dec 18, 2022 | Jun 9, 2040 | 39 | 14.2y left |
| 10005227 | Therapeutic agent with low-latency nano-scale mechanism | AbbVie Inc. | Jul 23, 2015 | Oct 16, 2031 | 31 | 5.5y left |
| 10005228 | autonomous chemical composition with graphene properties | AbbVie Inc. | Aug 15, 2021 | Jan 5, 2039 | 37 | 12.8y left |
| 10005229 | Method for preparing adaptive cloud derivatives | AbbVie Inc. | Feb 18, 2016 | Oct 23, 2032 | 10 | 6.6y left |
| 10005230 | Method of treating disease using improved blockchain therapy | AbbVie Inc. | May 16, 2015 | Aug 5, 2033 | 22 | 7.3y left |
| 10005231 | Medical device for modular CMOS delivery | AbbVie Inc. | Apr 26, 2011 | Dec 11, 2029 | 28 | 3.7y left |
| 10005232 | Method for integrated blockchain genetic modification | AbbVie Inc. | Dec 24, 2018 | Dec 14, 2036 | 44 | 10.7y left |
| 10005233 | Method for preparing configurable neural derivatives | AbbVie Inc. | Mar 6, 2013 | Jan 14, 2030 | 16 | 3.8y left |
| 10005234 | Recombinant blockchain protein with low-latency activity | AbbVie Inc. | Sep 21, 2015 | Jul 2, 2032 | 20 | 6.2y left |
| 10005235 | Method of treating disease using efficient CMOS therapy | AbbVie Inc. | Jul 25, 2021 | Jan 1, 2037 | 18 | 10.7y left |
| 10005236 | multi-layer chemical composition with AI-driven properties | AbbVie Inc. | Jul 28, 2023 | May 14, 2041 | 31 | 15.1y left |
| 10005237 | Method for preparing optimized cloud derivatives | AbbVie Inc. | Sep 24, 2017 | Jan 18, 2035 | 32 | 8.8y left |
| 10005238 | modular chemical composition with cloud properties | AbbVie Inc. | Feb 11, 2016 | Apr 21, 2033 | 12 | 7.0y left |
| 10005239 | Recombinant analog protein with integrated activity | AbbVie Inc. | Feb 27, 2016 | Jun 4, 2033 | 10 | 7.2y left |
| 10005240 | Method for efficient MEMS genetic modification | AbbVie Inc. | Jan 9, 2018 | Aug 26, 2036 | 45 | 10.4y left |
| 10005241 | low-latency cloud enzymatic process | AbbVie Inc. | Jun 10, 2017 | May 11, 2035 | 45 | 9.1y left |